Funded Tech Companies

Ratio Therapeutics

Wondering who provided funding to Ratio Therapeutics? Eli Lilly and Company, Duquesne Capital Management and Catalio Capital Management joined the equity holders in this biopharmaceutical company.

Company Overview

Contact Information

Company Background Information

Overview

A discovery through early clinical phase pharmaceutical company, Ratio Therapeutics employs a suite of innovative technologies to develop best-in-class targeted radiotherapeutics for the treatment of cancer. Ratio Therapeutics' Trillium� targeting scaffold combines pharmacokinetic modulation with best-in-class chelation technology to create proprietary small molecule targeting agents to attack a broad array of cancer targets. Our compounds accommodate imaging and therapeutic radioisotopes, ie "theranostics". The tunable nature of our platform combined with small-scale imaging trials in patients results in accelerated, de-risked compound selection.

Profile

Social Media

Company News

Facebook

YouTube

Last Transaction

8/3/2026

Financing History

Management Team

Title

Name

Email & Social

Chief Executive Officer

Jack Hoppin

        

Chief Financial Officer

Reed Malleck

        

Chief Operating Officer

Shawn Hillier

        

Chief Scientific Officer

John Babich

        

Chief Technical Officer

Matthias Friebe

        

Company Investors

• Eli Lilly and Company
• Duquesne Capital Management
• Catalio Capital Management
• Wasatch Equity Partners
• Bristol Myers Squibb
• The Pags Group
• Cornell University
• Schusterman Foundation

Browse more funded tech companies:

Ratio | Ratio.City

Share this article

About Our VC Funding Database

This tech company profile is powered by VentureDeal.com, a leading provider of venture capital transaction data.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary